Founded
2016
CEO
Ros Deegan
Founder
Professor Dame Carol Robinson
% Shareholding
49%
Stage
Pre-clinical
Number of employees
30+
Raised in an expanded Series A financing in February 2020
£27.5m

Unless stated all financials at 30 June 2021

Omass website

OMass Therapeutics is an Oxford University spin-out backed by Syncona and Oxford Science Enterprises that is using novel biochemistry techniques, native mass spectrometry and custom chemistry to deliver novel medicines against highly validated but inadequately drugged targets, with a focus on immunological and rare diseases.

OMass was founded on the realisation that small molecule drug discovery has historically focused on targets that operate in relative isolation, such as enzymes. However, many of the best targets operate within a broader ecosystem such as a membrane or an intracellular complex. To drug these targets, it is necessary to also interrogate their full scope of physical interactions within this broader ecosystem, with this being the focus of the OMass pipeline.  

The platform is based on work initiated by its scientific founders in the laboratory of Professor Carol Robinson at Oxford University and is currently being applied to an exciting pipeline of novel, differentiated small molecules against membrane and complex-bound targets, with a focus on areas with low translational risk where there is high potential to take products to market.

Investment opportunity

  • Opportunity to develop differentiated small molecule drugs leveraging a world-leading Native Mass Spectrometry platform which enables unique insights into membrane proteins and protein complexes such as GPCRs and Solute Carriers – classes of targets that have been historically difficult to drug in spite of high clinical relevance and unmet need.

Unmet medical need

  • Undisclosed programmes are all in indications with significant unmet medical need

Key risks

  • Attrition of potential drugs

The Omass Therapeutics pipeline

Research Pre-clinical Clinical
  • MC2 in orphan endocrine disorders

  • GPR65 in IBD

  • Gasdermin in broad immunology

  • KCC2 in epilepsy including rare epilepsy

  • SLC15A4 in lupus and other IFN-opathies

Syncona team

Martin Murphy

Martin Murphy

Martin is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 alongside The Wellcome Trust. Since then, Martin has been closely involved in the foundation and development of seven Syncona companies, including: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon and Resolution Therapeutics. He is Chairman of Quell and Anaveon and i…
View Martin's biography
Position
Board observer
Qualification
PhD
Magdalena Jonikas

Magdalena Jonikas

Magdalena is a Partner of Syncona Investment Management Ltd. She is a Director on the Board of OMass Therapeutics. Previously, she was an Associate Partner at McKinsey & Company where she specialised in pharmaceuticals Research & Development, portfolio management and Business Development and Licensing. Magdalena holds a PhD in Bioengineering from Stanford University and was a postdoctoral…
View Magdalena's biography
Position
Board member
Qualification
PhD
Edward Hodgkin

Edward Hodgkin

Edward Hodgkin is a Partner of Syncona Investment Management Ltd. He is currently Chairman & CEO of Resolution Therapeutics and Chairman of OMass Therapeutics, and was previously the first CEO and a board member of Autolus Therapeutics (NASDAQ:AUTL). Within the Syncona life science team, he is involved in creation of new businesses and then fills executive roles within those companies to make…
View Edward's biography
Position
Chair
Qualification
PhD

OMass Therapeutics leaders and founders

Professor Dame Carol Robinson

Professor Dame Carol Robinson

Founder and Scientific Advisor
Dr Jonathan Hopper

Dr Jonathan Hopper

Founder and Vice President, Platforms
Dr Idlir Liko

Dr Idlir Liko

Founder and Director of Technology